Answers are grounded in this paper and cite their sources.
What is nirogacestat and how does it work? Nirogacestat is an oral, selective, small molecule gamma secretase inhibitor. Through selective inhibition of gamma-secretase-mediated cleavage, of the Notch receptor, which when dysregulated can activate pathways causing tumor growth. What is this approved for? Nirogacestat is FDA approved for treatment of progressing desmoid tumors in adult patients requiring systemic therapy. What is the basis for this approval? Nirogacestat was approved based on results of the Phase III DeFi trial in the New England Journal of Medicine (2023; doi:10.1056/NEJMoa2210140). This was a Phase III, international, double-blind, randomized, placebo-controlled trial in adults with progressing desmoid tumors not amendable to surgery. Patients were randomized to receive 150 mg nirogacestat or placebo by mouth twice daily until disease progression or unacceptable toxicity. The primary endpoint showed improvement in progression-free survival with a risk reduction of disease progression of 71 percent compared to placebo. The median PFS was not reached in the treatment arm. Objective response rate was 41 percent in the treatment arm versus 8 percent in the placebo arm. Patient-reported quality-of-life outcomes, such as pain, tumor-specific symptoms, physical functioning, and overall quality of life, also demonstrated sustained improvements. How do you administer nirogacestat? Nirogacestat is available as a 50 mg tablet and administered orally at a dose of 150 mg twice daily. Tablets should be swallowed whole and can be taken without regard to food. The manufacturer's package insert provides guidance on starting dose, as well as dose reductions due to toxicity. Are there any pre-medications needed? Nirogacestat has a low emetic risk. No routine pre-medications are recommended. What are common side effects with nirogacestat? The most common adverse events were diarrhea (86%), nausea (54%), fatigue (51%), hypophosphatemia (42%), maculopapular rash (32%), stomatitis (29%), headache (29%), and vomiting (20%). What are uncommon side effects with nirogacestat? Rash (19%), hot flush (19%), alopecia (19%), ALT increase (17%), upper respiratory tract infection (17%), and weight gain (16%). What serious warning and precautions exist for nirogacestat? Diarrhea, ovarian toxicity, hepatotoxicity, non-melanoma skin cancers, electrolyte abnormalities, and embryo-fetal toxicity. Are there any important drug interactions to be aware of? Nirogacestat is primarily metabolized by CYP3A4. Coadministration with strong or moderate CYP3A4 inhibitors should be avoided due to the potential to increase nirogacestat exposure. Additionally, coadministration with a strong or moderate CYP3A4 inducer should be avoided due to the potential to decrease nirogacestat exposure. Use of gastric acid-reducing agents (i.e., proton pump inhibitors and H2-receptor antagonist) should be avoided. Antacids may be administered; however, they should be staggered to avoid altering absorption of nirogacestat. How do I adjust the dose in the setting of renal or hepatic insufficiency? There are no dose adjustments provided in manufacturer labeling for renal or hepatic impairment existing prior to treatment. In pharmacokinetic studies, there's no significant difference for patients with an eGFR >41 mL/min/1.73 m2. In moderate hepatic impairment, there was a mean AUC increase of 16 percent and mean Cmax decreased by up to 39 percent. Nirogacestat has not been studied in patients with severe hepatic impairment. What should my patients know about nirogacestat? Pregnancy should be avoided due to the risk for embryo-fetal toxicity and both men and women should use effective contraception during treatment and at least 1 week following the last dose of nirogacestat. Breastfeeding should be avoided during treatment and at least 1 week after the last dose. Fertility and ovarian function may be impaired in patients on nirogacestat and the long-term impact on fertility has not been established. What else should I know about nirogacestat? A comprehensive medication review is recommended at the start of treatment. If a patient is started on new medications, it is recommended to evaluate for drug-drug interactions as nirogacestat has significant drug interactions with one of the most common CYP pathways, CYP3A4. Diarrhea can occur while on nirogacestat and can be severe. A majority of patients treated developed diarrhea and Grade 3 events were also observed. The median time to onset of the first diarrhea event was 9 days. Education related to management of diarrhea with antidiarrheal medications is recommended. Treatment with nirogacestat may result in the occurrence of new nonmelanoma skin cancers, including cutaneous squamous cell carcinoma, as well as basal cell carcinoma. It is recommended to perform a dermatologic exam prior to initiation of therapy and routinely during treatment. What useful links are available? FDA Approval: http://tinyurl.com/2p984rs7 Prescribing Information: http://tinyurl.com/bd54xhvs Any ongoing clinical trials? Nirogacestat is also being studied in clinical trials of various phases in patients with ovarian granulosa cell tumor, multiple myeloma, etc. More information is available about these trials at clinicaltrials.gov. SASHA HAARBERG, PHARMD, BCOP, is Clinical Oncology Pharmacist at the Siteman Cancer Center and Washington University School of Medicine. JANELLE E. MANN, PHARMD, BCOP, is Clinical Oncology Pharmacist/Manager, Clinical Pharmacy Services at Washington University School of Medicine. She serves as the Pharmacy Forum column editor. RAMASWAMY GOVINDAN, MD, is Professor of Medicine; Anheuser Busch Chair in Medical Oncology; Director, Section of Medical Oncology, Division of Oncology, Washington University School of Medicine. He serves as the Pharmacy Forum column physician advisor.Sasha Haarberg, PharmD, BCOP: Sasha Haarberg, PharmD, BCOPJanelle E. Mann, PharmD, BCOP: Janelle E. Mann, PharmD, BCOPRamaswamy Govindan, MD: Ramaswamy Govindan, MD
No takes yet. Share an insight, caveat, or question.
Sasha Haarberg (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: